The spasm shuts off the flow of blood to part of the heart, which results in a heart attack
Like with any med, tirzepatide has potential side effects
Tirzepatide (Mounjaro for T2DM, Zepbound for obesity): a dual GLP-1/GIP agonist
Abouhussein DMN
The greater magnitudes of bodyweight reduction seen in this trial, as well as the improvements in cardiovascular risk factors and glucose control, can have beneficial effects on health goals in clinical practice. In the STEP UP T2D trial, a higher semaglutide dose resulted in an average bodyweight reduction of 13.2%, compared to 10.4% for the standard dose and 3.9% for the placebo
Metabolic unpredictability: Simultaneously altering multiple metabolic pathways incretin signalling, glucagon activity, and NAD+ metabolism without clinical oversight introduces unpredictable physiological consequences